A Prospective, Active-controlled, Randomized, Double-blind, Multicenter, Phase III Study to Compare the Safety and Efficacy of Biosimilar Denosumab vs Reference Denosumab in the Treatment of Postmenopausal Osteoporosis
Journal of The Association of Physicians of India · 2025
DOI: 10.59556/japi.73.0772 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of The Association of Physicians of India, 2025. Verfasst von Thomas Paul und 28 weiteren Autor:innen. Beteiligte Einrichtung: Professor, Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India. Hauptthemen laut MEDLINE: Denosumab, Osteoporosis, Postmenopausal, Biosimilar Pharmaceuticals, Bone Density Conservation Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Professor, Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India.
- Professor, Department of Orthopedics, All India Institute of Medical Sciences, New Delhi, India.
- Professor, Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, Tamil Nadu, India.
- Consultant Orthopedic Surgeon, Life Point Hospital, Pune, Maharashtra, India.
- Director and Chief Orthopedic Surgeon, Ishwar Institute of Healthcare, Aurangabad, Maharashtra, India.
- Consultant Endocrinologist, Getwell Hospital and Research Institute, Nagpur, Maharashtra, India.
Zitieren
APA
Paul, T., Garg, B., Kapoor, N., Patil, V., Kachnerkar, N., Shembalkar, J., Purohit, S., Maheshwari, S., Maheshwari, S., Yadav, A., Cherian, J. J., Agrawal, A., Basu, K., Tripathy, S. K., Pongde, A. B., Goni, V., Markade, P., Makane, A., Tiwaskar, M., …, & Sharma, A. (2025). A Prospective, Active-controlled, Randomized, Double-blind, Multicenter, Phase III Study to Compare the Safety and Efficacy of Biosimilar Denosumab vs Reference Denosumab in the Treatment of Postmenopausal Osteoporosis. Journal of The Association of Physicians of India. https://doi.org/10.59556/japi.73.0772
Vancouver
Paul T, Garg B, Kapoor N, Patil V, Kachnerkar N, Shembalkar J, et al. A Prospective, Active-controlled, Randomized, Double-blind, Multicenter, Phase III Study to Compare the Safety and Efficacy of Biosimilar Denosumab vs Reference Denosumab in the Treatment of Postmenopausal Osteoporosis. Journal of The Association of Physicians of India. 2025. doi:10.59556/japi.73.0772
BibTeX
@article{Paul2025,
author = {Paul, Thomas and Garg, Bhavuk and Kapoor, Nitin and Patil, Vishal and Kachnerkar, Nilesh and Shembalkar, Jayashri and Purohit, Sharad and Maheshwari, Sunil and Maheshwari, Surabhi and Yadav, Awadhesh and Cherian, Joe Joseph and Agrawal, Anubhav and Basu, Kaushik and Tripathy, Sujit Kumar and Pongde, Ashish B and Goni, Vijay and Markade, Pravin and Makane, Abhimanyu and Tiwaskar, Mangesh and Cherian, Kripa Elizabeth and Rane, Yogesh and Shahavi, Vinayak and Poojary, Vivek and Somani, Rahul and Gondane, Ajitkumar and Aiwale, Amol and Pawar, Dattatray and Pawar, Roshan and Sharma, Akhilesh},
title = {A Prospective, Active-controlled, Randomized, Double-blind, Multicenter, Phase III Study to Compare the Safety and Efficacy of Biosimilar Denosumab vs Reference Denosumab in the Treatment of Postmenopausal Osteoporosis},
journal = {Journal of The Association of Physicians of India},
year = {2025},
doi = {10.59556/japi.73.0772}
}
EUVIMED